基因工程的人类肌肉原始细胞可以减少免疫排斥
Yu Chen1,2,3, Peng Wang1,3, Shilin Ma1,2,3
1Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
Cell proliferation
|January 8, 2025
概括
工程化低免疫细胞克服了移植排斥和亡. 通过修改免疫蛋白和增强抗亡因子,这些细胞提高了移植存活率.
科学领域:
- 细胞和分子生物学 细胞和分子生物学
- 免疫学 免疫学 免疫学
- 移植科学 移植科学
背景情况:
- 细胞移植面临着重大障碍,包括因恶劣的移植环境而导致的淋巴细胞免疫排斥和亡.
- 现有的细胞疗法受到宿主免疫反应和移植后细胞应激的限制.
相关概念视频
Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
Satellite Stem Cells and Muscular Dystrophy
1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K
Cell-mediated Immune Responses
66.8K
Overview
66.8K


